An Opportunity for FDA and Rare Disease
Rare disease research and drug development are at a transformative crossroads, with the FDA uniquely positioned to lead the charge in accelerating innovation. By embracing legislative support, fostering collaboration with the NIH, and adopting flexible regulatory models, the FDA can redefine the future of clinical trials for rare diseases. This shift will not only address […]